TipRanks
Advertisement
Advertisement
Nektar 60% selloff brings ‘attractive buying opportunity,’ says Citi
PremiumThe FlyNektar 60% selloff brings ‘attractive buying opportunity,’ says Citi
18d ago
Buy Rating Reaffirmed on Rezpeg’s Differentiated Profile; Price Target Maintained at $151
Premium
Ratings
Buy Rating Reaffirmed on Rezpeg’s Differentiated Profile; Price Target Maintained at $151
18d ago
Nektar selloff yesterday overdone, says H.C. Wainwright
Premium
The Fly
Nektar selloff yesterday overdone, says H.C. Wainwright
21d ago
Nektar falls -19.8%
PremiumThe FlyNektar falls -19.8%
22d ago
Nektar shares long-term dermatology data on rezpegaldesleukin
Premium
Company Announcements
Nektar shares long-term dermatology data on rezpegaldesleukin
22d ago
Nektar’s rezpegaldesleukin shows efficacy in alopecia and atopic dermatitis
Premium
The Fly
Nektar’s rezpegaldesleukin shows efficacy in alopecia and atopic dermatitis
22d ago
Nektar selloff on trial brings ‘strong entry point,’ says BTIG
PremiumThe FlyNektar selloff on trial brings ‘strong entry point,’ says BTIG
26d ago
Nektar Wins $90 Million Verdict in Lilly Dispute
Premium
Company Announcements
Nektar Wins $90 Million Verdict in Lilly Dispute
28d ago
Nektar shares pressured by jury notes in Lilly case, says B. Riley
Premium
The Fly
Nektar shares pressured by jury notes in Lilly case, says B. Riley
1M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―